Testing CHT101 cell therapy for brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new cell therapy called CHT101 for people with recurrent or worsening brain tumors. The therapy uses your own immune cells that are modified to target a protein called CD70 on the tumor. It is for adults with certain types of brain cancer that have returned or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific protein called CD70, which will be checked by a lab test.
- You must have a high-grade glioma (a fast-growing brain tumor) or a type of lymphoma in the central nervous system.
- You need to have at least one brain tumor that can be seen on an MRI scan.
- You should be able to carry on daily activities (Karnofsky score of 70 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new type of immune cell therapy (CAR-T) that targets a protein called CD70 found on some solid tumors. It is for people whose cancer has not responded to other treatments and whose tumor tests positive for CD70. The goal is to see if this treatment can help shrink tumors.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Hear when a new Brain (Nervous System) Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.